Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update

Atyr PHARMA INC (NASDAQ:ATYR) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 685,800 shares, an increase of 55.5% from the August 31st total of 440,900 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average trading volume of 371,400 shares, the days-to-cover ratio is presently 1.8 days.

Analyst Ratings Changes

Several research analysts have weighed in on ATYR shares. Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a report on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Thursday, August 15th.

Atyr PHARMA Trading Up 1.2 %

Shares of ATYR stock opened at $1.74 on Friday. The firm has a market cap of $131.89 million, a P/E ratio of -1.93 and a beta of 1.22. The company has a quick ratio of 7.63, a current ratio of 7.63 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $1.87. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50.

Atyr PHARMA (NASDAQ:ATYR) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. As a group, research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current year.

Insider Transactions at Atyr PHARMA

In other Atyr PHARMA news, Director Paul Schimmel bought 41,052 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of $1.74 per share, with a total value of $71,430.48. Following the purchase, the director now owns 354,075 shares in the company, valued at approximately $616,090.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.70% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.